FLT3 and acute myeloid leukemia: Interestingly, MPI was amongst the top drop-out genes in our published CRISPR-Cas9 screen aiming to identify sensitizers to the clinical grade FLT3-tyrosine kinase inhibitor (TKI) AC220 (quizartinib) in AML carrying activating FLT3 internal tandem duplication (ITD) mutations9 and more recently was identified amongst 81 United States Food and Drug Administration (FDA) druggable genetic dependencies of a murine model of FLT3ITD AML24.